We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Kenya's Parliament on Thursday rejected proposed amendments to its patent law, some of which had the potential decrease access to antiretroviral drugs.
The FDA has approved this year's seasonal influenza vaccines that include the new strains of virus judged likely to cause flu in the Northern Hemisphere in 20062007.
The Indian Drugs Manufacturers Association (IDMA) has asked the government to notify it of the revised ceiling prices of drugs as soon as possible to help drugmakers prepare the inventory of packing materials for batches to be manufactured after Oct. 2 in compliance with the new tax plan.
The Ministry of Health, Labor and Welfare in Japan has approved Alcon's Vegamoxt (moxifloxacin hydrochloride ophthalmic solution) 0.5 percent for the treatment of bacterial infections of the eye including, among others, conjunctivitis and keratitis (including corneal ulcer), as well as for surgical prophylaxis.
Baxter Corporation (Canada) announced that Health Canada has approved ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM)] for the prevention and control of bleeding episodes in people with hemophilia A (classical hemophilia).
POZEN Inc. announced that it has signed an exclusive global collaboration agreement with AstraZeneca for the co-development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet.
Schering-Plough Corporation has announced that the Japan Ministry of Health, Labor and Welfare (MHLW) has approved TEMODAL (temozolomide) Capsules for the treatment of malignant glioma.
Oscient Pharmaceuticals Corporation said its antibiotic Factive has been approved by the Ministry of Health in Mexico as a five-day treatment for three illnesses.
Takeda Pharmaceutical has informed BioNumerik Pharmaceuticals that it is considering terminating their alliance over Tavocept after the drug candidate failed to meet the primary endpoints of two Phase III trials in cancer patients.